Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UCBSTU:UNC +0.52%90 5-Year Yield-on-Cost % is 0.65 as of Jul. 30, 2026, which is 62% below its 10-year median of 1.69. GuruFocus rates STU:UNC with a GF Score™ of 90/100 and a GF Value™ of €212.43 (Modestly Overvalued). Among 150 Biotechnology companies, UCB ranks worse than 77.33% on this metric.
UCB's yield on cost for the quarter that ended in Dec. 2025 was 0.65.
The historical rank and industry rank for UCB's 5-Year Yield-on-Cost % or its related term are showing as below:
STU:UNC'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.56 Med: 1.69 Max: 2.22
Current: 0.65
During the past 13 years, UCB's highest Yield on Cost was 2.22. The lowest was 0.56. And the median was 1.69.
STU:UNC's 5-Year Yield-on-Cost % is ranked worse than 77.33% of 150
companies
in the Biotechnology industry
Industry Median: 1.695
vs STU:UNC: 0.65
UCB (STU:UNC) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
UCB 5-Year Yield-on-Cost % Related Terms
STU:UNC vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, UCB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where UCB's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
UCB (STU:UNC) has a 5-Year Yield-on-Cost % of 0.65 as of Jul. 30, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on UCB and its competitors. This is 62% below median its historical median of 1.69. Over the past decade, UCB's 5-Year Yield-on-Cost % has ranged from 0.56 to 2.22. According to the industry distribution chart, UCB ranks #116 out of 150 companies in the Biotechnology industry, placing it in the top 77.3%.
Is UCB's 5-Year Yield-on-Cost % too high?
UCB's current 5-Year Yield-on-Cost % of 0.65 is 62% below median its 10-year median of 1.69. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 2.22. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.70. UCB's value of 0.65 is 61.7% below this industry median. Based on the distribution chart, UCB ranks #116 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, UCB has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #116 out of 150 companies for 5-Year Yield-on-Cost %. This places UCB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.70. UCB's value of 0.65 is 61.7% below this benchmark. Historically, UCB's own 5-Year Yield-on-Cost % has ranged from 0.56 to 2.22 over the past decade. While the company's 10-year median is 1.69 vs. the industry median of 1.70, UCB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UCB's current 5-Year Yield-on-Cost % of 0.65 is 61.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on UCB and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UCB's current 5-Year Yield-on-Cost % is 0.65, which is 62% below median its own 10-year median of 1.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €212.43, compared to a current price of €251.00 — trading 18.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.65, which is 62% below median its 10-year median of 1.69 and 61.7% below the Biotechnology industry median of 1.70. UCB's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For UCB (STU:UNC), the current 5-Year Yield-on-Cost % is 0.65 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (STU:UNC) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be overvalued.
The current stock price of €251.00 is trading 18.2% above its estimated GF Value™ of €212.43.
GuruFocus considers UCB to be Modestly Overvalued.
Key valuation signals for STU:UNC:
5-Year Yield-on-Cost %: 0.65 (62% below median its 10-year median of 1.69)
GF Value™: €212.43 vs. price of €251.00 (18.2% above fair value)
Industry Position: 61.7% below the Biotechnology median (#116 of 150)
No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
90GF Score
Get the complete analysis for STU:UNC
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:UNC has been successfully added to your 
